Comparative cost-effectiveness of HPV mRNA and DNA testing for anal cancer screening in MSM living with HIV: a model-based study

Anal cancer incidence is increasing among men who have sex with men (MSM) living with HIV, driven by persistent high-risk (HR) HPV infection. HPV mRNA testing may offer higher specificity for detecting high-grade squamous intraepithelial lesions (HSIL) than cytology or HPV DNA testing, with potential economic implications. We evaluated the cost-effectiveness of screening strategies combining HPV biomarkers and post-high-resolution anoscopy (HRA) management. A Markov model simulated a cohort of MSM living with HIV to assess 45 screening strategies varying by algorithm (cytology, co-testing, HPV reflex), HPV assay (DNA-hybridization, DNA-PCR, mRNA), and post-HRA management (follow-up, infrared coagulation [IRC], trichloroacetic acid [TCA]). Outcomes included HSIL and anal cancer cases, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Strategies involving treatment reduced anal cancer incidence by 43–69% compared with no screening, with greater reductions for co-testing. Cytology was the most cost-effective option at €25 per test. At €6, co-testing became competitive, particularly with HR-HPV assays—DNA-hybridization (€13,203/QALY) and mRNA (€14,482/QALY). All optimal strategies included TCA. Anal cancer screening in MSM living with HIV is effective and cost-effective. Co-testing with cytology and HR-HPV assays—whether DNA or mRNA—combined with post-HRA treatment provided the greatest health benefits, while its cost-effectiveness depended strongly on HPV test cost and became favorable at lower HPV test costs. HPV mRNA-based approaches provided a comparable and viable alternative to HPV DNA.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-19
DOI
https://doi.org/10.1038/s41598-026-75472-6
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative cost-effectiveness of HPV mRNA and DNA testing for anal cancer screening in MSM living with HIV: a model-based study

Alexandra Montoliu, María Saumoy, David Gómez-Guillén, Ana Silva‐Klug et al.
1 links
Scientific Reports
Cervical Cancer and HPV Research
article

Comparative cost-effectiveness of HPV mRNA and DNA testing for anal cancer screening in MSM living with HIV: a model-based study

Alexandra Montoliu, María Saumoy, David Gómez-Guillén, Ana Silva‐Klug, Loris Trenti, Mireia Díaz, Sònia Paytubi, Núria Baixeras, Daniel Podzamczer, Laia Alemany, Montserrat Torres
article en

Abstract

Anal cancer incidence is increasing among men who have sex with men (MSM) living with HIV, driven by persistent high-risk (HR) HPV infection. HPV mRNA testing may offer higher specificity for detecting high-grade squamous intraepithelial lesions (HSIL) than cytology or HPV DNA testing, with potential economic implications. We evaluated the cost-effectiveness of screening strategies combining HPV biomarkers and post-high-resolution anoscopy (HRA) management. A Markov model simulated a cohort of MSM living with HIV to assess 45 screening strategies varying by algorithm (cytology, co-testing, HPV reflex), HPV assay (DNA-hybridization, DNA-PCR, mRNA), and post-HRA management (follow-up, infrared coagulation [IRC], trichloroacetic acid [TCA]). Outcomes included HSIL and anal cancer cases, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Strategies involving treatment reduced anal cancer incidence by 43–69% compared with no screening, with greater reductions for co-testing. Cytology was the most cost-effective option at €25 per test. At €6, co-testing became competitive, particularly with HR-HPV assays—DNA-hybridization (€13,203/QALY) and mRNA (€14,482/QALY). All optimal strategies included TCA. Anal cancer screening in MSM living with HIV is effective and cost-effective. Co-testing with cytology and HR-HPV assays—whether DNA or mRNA—combined with post-HRA treatment provided the greatest health benefits, while its cost-effectiveness depended strongly on HPV test cost and became favorable at lower HPV test costs. HPV mRNA-based approaches provided a comparable and viable alternative to HPV DNA.

Scientific Reports
Instituto de Salud Carlos III (ES), Bellvitge University Hospital (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Institut Català d'Oncologia (ES), Barcelona Institute for Global Health (ES), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Fundació Lluita contra les Infeccions (ES), Medical Research Network (US)
Good health and well-being
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon